Literature DB >> 30698359

Risk-benefit point of the Model for End-stage Liver Disease score in patients waiting for deceased-donor liver transplantation: A single-center experience.

Sena Iwamura1, Toshimi Kaido1, Satoshi Morita2, Yosuke Miyachi1, Siyuan Yao1, Hisaya Shirai1, Atsushi Kobayashi1, Yuhei Hamaguchi1, Naoko Kamo1, Shintaro Yagi1, Shinji Uemoto1.   

Abstract

AIM: To clarify the risk-benefit point of the Model for End-stage Liver Disease (MELD) score in patients waiting for deceased-donor liver transplantation (DDLT).
METHODS: The present study retrospectively investigated 213 patients registered on the waiting list at Kyoto University (Kyoto, Japan) between 2005 and 2016. Patients were stratified by MELD score (6-9/10-14/15-20/21-30/31-40) and classified into two groups: the DDLT group (30 patients) and the waiting group (183 patients). Their post-registration mortality risk and long-term survival were compared.
RESULTS: For all MELD categories, the mortality risk was lower in the DDLT group than in the waiting group. The hazard ratio of post-registration mortality decreased in the DDLT group compared to the waiting group as the MELD score increased (0.36/0.12/0.06/0.042/0.004). Survival was significantly better among patients in the DDLT group with a MELD score of 15 or more than among patients in the waiting group.
CONCLUSION: For all MELD categories, DDLT reduced the mortality risk of patients on the waiting list.
© 2019 The Japan Society of Hepatology.

Entities:  

Keywords:  DDLT; MELD score; waitlist mortality

Year:  2019        PMID: 30698359     DOI: 10.1111/hepr.13320

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  1 in total

1.  Prognostic index consisting of early post-transplant variables <2 weeks in adult living-donor liver transplantation.

Authors:  Jiro Kusakabe; Koichiro Hata; Shiro Tanaka; Katsuhiro Omae; Yusuke Okamura; Tetsuya Tajima; Ichiro Tamaki; Hidetaka Miyauchi; Toyonari Kubota; Hirokazu Tanaka; Shinji Uemoto
Journal:  Hepatol Res       Date:  2020-02-18       Impact factor: 4.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.